Clinical trials: Locally Advanced Head and Neck Carcinoma
Esophageal Squamous Cell Carcinoma
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell carcinoma, the investigators designed a prospective, randomized, controlled , multicente phase II trial, to investigate the efficacy and…
- Trial name
- NTNC (NCT03964753)
- Testing
- Nab-paclitaxel and Cisplatin, surgery
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Cancer
Treatment Selection According to Skin Reaction to Cetuximab
The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e.
- Trial name
- NCT01472653
- Testing
- cisplatin, radiotherapy, cetuximab
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- Institute of Oncology Ljubljana
Esophageal Cancer
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00655876
- Testing
- cetuximab, cisplatin, paclitaxel
- Where
- 175 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Previous studies confirmed locally advanced oral/oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients with a pathological response had higher probability of survival in neoadjuvant settings.
- Trial name
- NCT06009861
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- Peking University Hospital of Stomatology
Locally Advanced Head and Neck Squamous Cell Carcinoma
Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label, randomized, controlled, exploratory clinical trial designed to evaluate the efficacy and safety of de-escalated surgery compared with standard surgery in patients with resectable locally…
- Trial name
- NCT07369882
- Testing
- Radical surgery combined with radiotherapy or chemoradiotherapy, Surgical De-escalation After Neoadjuvant Therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qunxing Li,MD
Head and Neck Neoplasms, Laryngeal Neoplasms
Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
BACKGROUND: Concomitant radiotherapy and cisplatin (CDDP) based chemotherapy is the standard treatment for LA-NHSCC. This combined modality treatment is linked with considerable acute local and systemic toxicity.EGFR is…
- Conditions
- Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Pharyngeal Neoplasms
- Trial name
- CTXMAB+RT (NCT01216020)
- Testing
- cetuximab, cisplatin (associated to radiotherapy)
- Where
- 7 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Azienda USL 4 Prato
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Head and Neck Cancer, Oropharyngeal Cancer
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
In this study the safety \& feasibility of image-guided mid-treatment hyper-fractioned dose-escalation with proton therapy will be assessed for the treatment of locally advanced HPV-negative squamous cell oropharyngeal cancer
- Trial name
- PIRATES (NCT06446713)
- Testing
- Image guided hybrid hyper-fractioned dose escalation with proton therapy
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- University Medical Center Groningen
Esophageal Neoplasms
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
This phase Ⅰ/Ⅱ trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for locally advanced esophageal carcinoma.
- Trial name
- NCT02429622
- Testing
- IMRT simultaneous integrated boost, Paclitaxel, Nedaplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive…
- Conditions
- Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
- Trial name
- NCT07172256
- Testing
- CUE-101, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yale University
Nasopharyngeal Carcinoma
Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma
The study is to observe the efficacy and toxicity of demethylating drug decitabine and cisplatin induced chemotherapy for 3 cycles followed by concurrent chemoradiotherapy in the treatment of regionally advanced nasopharyngeal…
- Trial name
- NCT03701451
- Testing
- Demethylated drug decitabine
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
The objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided…
- Trial name
- NCT05522985
- Testing
- AP combined with or without Toripalimab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Nasopharyngeal Neoplasms, PD-1 Inhibitor
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined…
- Conditions
- Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
- Trial name
- NCT06811844
- Testing
- Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy
- Where
- 3 sites in China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal…
- Trial name
- NCT05650216
- Testing
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Squamous Cell Carcinoma of Head and Neck
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
This is a Phase I dose-escalation study of sEphB4-HSA in combination with chemotherapy, cetuximab and radiotherapy (RT). The purpose is to estimate the maximum tolerated dose (MTD) that can be administered concurrently with…
- Trial name
- NCT04091867
- Testing
- sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma, Radiotherapy
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma
This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Radiotherapy, Immunotherapy, Surgery
- Trial name
- iCSDeR (NCT05476965)
- Testing
- induction therapy; surgery; radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hubei Cancer Hospital
Esophageal Squamous Cell Carcinoma
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal…
- Trial name
- NCT05495152
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Henan Cancer Hospital